Meeting the Discovery Challenge of Drug-Resistant Infections
REVIEWS Drug Discovery Today Volume 24, Number 2 February 2019 Teaser In this Keynote we consider recent progress with the antibiotic discovery process and make recommendations for further, often collaborative, advances. Reviews KEYNOTE REVIEW Meeting the discovery challenge of drug-resistant infections: progress and focusing resources 1,2 3 4 Gordon Dougan is a Senior Gordon Dougan , Chris Dowson and John Overington Scientist at The Wellcome Trust Sanger Institute Next Generation Antibiotic Discovery Symposium (Cambridge, UK), a Professor Participants in the Department of Medicine at Cambridge University and a 1 Fellow of Wolfson College. His The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK 2 research focuses on enteric The Department of Medicine, University of Cambridge, UK pathogens with a strong 3 University of Warwick, Coventry, UK emphasis on basic pathogenic mechanisms and 4 immunology. He contributes to the Mouse Genetic Medicine Discovery Catapult, Mereside, Alderly Park, Alderly Edge, Cheshire, UK Programme running an infection screen in novel gene KO strains. Gordon has a particular interest in using genomics to study host–pathogen interactions. Following multiple warnings from governments and health organisations, Chris Dowson holds a there has been renewed investment, led by the public sector, in the personal chair at Warwick discovery of novel antimicrobials to meet the challenge of rising levels of University and is a member of the Medical Research drug-resistant infection, particularly in the case of resistance to antibiotics. Council Infections and Immunity Board. His Initiatives have also been announced to support and enable the antibiotic research focuses on the discovery process. In January 2018, the Medicines Discovery Catapult, UK, emergence and evolution of antibiotic resistance across a hosted a symposium: Next Generation Antibiotics Discovery, to consider wide range of bacteria.
[Show full text]